SGLT2 Inhibitors Do Not Significantly Increase UTI Risk
Large clinical trials have consistently shown no difference in rates of urinary tract infections or serious urinary tract infections between SGLT2 inhibitors and placebo 1. This evidence directly contradicts theoretical concerns about UTI risk from glycosuria.
Evidence from Major Guidelines
The 2018 ACC Expert Consensus explicitly states: "Although there have been spontaneous postmarketing reports of pyelonephritis and urosepsis requiring hospitalization in patients receiving SGLT2 inhibitors, large clinical trials have shown no difference in the rates of any urinary tract infections or serious urinary tract infections between SGLT2 inhibitors and placebo" 1.
Multiple recent guidelines (2022-2025) acknowledge genitourinary side effects occur at 2-10% rates, but consistently distinguish between:
- Genital mycotic infections (well-established increased risk, especially in women)
- Urinary tract infections (no significant increase demonstrated) 2
The 2022 KDIGO/ADA consensus notes that genital mycotic infections occurred in 6% of SGLT2i users versus 1% of placebo, but makes no similar claim about UTIs 3.
Recent High-Quality Research Evidence
The most recent and highest quality evidence comes from a 2026 trial-level meta-analysis 4 of 14 randomized placebo-controlled trials across type 2 diabetes, heart failure, and chronic kidney disease:
Primary any-UTI analysis: 11 studies, 62,542 participants, 4,685 events
- Pooled RR 1.14 (95% CI 0.99-1.32; P=0.073) - not statistically significant
- Sensitivity analysis: RR 1.08 (95% CI 1.00-1.18; P=0.060) - still not significant
Serious/complicated UTI analysis: 7 studies, 34,396 participants, 339 events
- Pooled RR 0.99 (95% CI 0.78-1.27; P=0.960) - no increased risk
- No heterogeneity detected (I²=0.0%)
This meta-analysis concludes that urinary safety concerns should not be considered equivalent to the established excess risk of external genital infection 4.
Supporting Population-Based Studies
Multiple large real-world studies corroborate these findings:
2026 Danish surveillance study (198,613 initiation episodes): No increased UTI risk from 2016 onward; HRs remained under 1.0 for bacterial UTI-related prescriptions 5
2025 Korean NHIS study (27,128 patients): HR 0.874 (95% CI 0.585-1.309; P=0.510) - no significant increase 6
2023 Japanese nationwide claims database: SGLT2i prescription was negatively associated with UTI likelihood in males (OR 0.74) and showed no difference in females (OR 0.99) 7
2022 UK/Canadian propensity-matched cohort: No increased UTI risk versus DPP-4 inhibitors (HR 1.08), sulfonylureas (HR 1.08), GLP-1 RAs (HR 0.81), or TZDs (HR 0.81); lower risk versus insulin (HR 0.74) 8
Clinical Implications
Do not withhold SGLT2 inhibitors due to UTI concerns, even in patients with:
- Prior history of UTIs 9
- Immune-mediated inflammatory diseases on immunosuppression 10
- Female sex (though genital mycotic infections are more common) 11
Key Distinctions for Practice:
Genital mycotic infections (candida vaginitis in women, balanitis in men):
Urinary tract infections:
Patient Counseling:
- Educate about genital hygiene to prevent mycotic infections 12, 13
- Distinguish between lower genital symptoms (more common, less serious) versus true UTI symptoms
- Monitor for signs of rare serious infections (pyelonephritis, urosepsis) but recognize these are not more common than placebo 1
The cardiovascular, renal, and mortality benefits of SGLT2 inhibitors far outweigh the minimal to absent UTI risk, making concerns about UTIs an inappropriate reason to avoid this guideline-directed therapy 2, 14, 15, 16.